Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987011 | 0.87 | PKM (0.46) | LMNAALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4985224 | 0.86 | AKR1C3 (0.42) | KMT2AMEN1AKR1C3GBA1 | |
| SCHEMBL4980960 | 0.86 | SMN1; SMN2 (0.46) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL4983020 | 0.86 | MEN1 (0.47) | ALDH1A1KMT2AMEN1AKR1C3L3MBTL1 | |
| SCHEMBL4987187 | 0.85 | ALDH1A1 (0.46) | LMNAALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4985245 | 0.85 | LMNA (0.38) | LMNAALDH1A1SMN1; SMN2KMT2AAKR1C3 | |
| SCHEMBL4983067 | 0.85 | PKM (0.43) | LMNAALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4988448 | 0.85 | MEN1 (0.45) | ALDH1A1KMT2AMEN1AKR1C3GBA1 | |
| SCHEMBL4982876 | 0.84 | HDAC6 (0.40) | LMNAALDH1A1SMN1; SMN2AKR1C3L3MBTL1 | |
| SCHEMBL4988327 | 0.84 | GBA1 (0.48) | LMNAALDH1A1KMT2AMEN1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | LMNA 1911/4885ALDH1A1 3640/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.